Merkel cell carcinoma is a highly aggressive cutaneous neuroendocrine tumor that has been associated with Merkel cell polyomavirus in up to 80% of cases. Merkel cell polyomavirus is believed to influence pathogenesis, at least in part, through expression of the large T antigen, which includes a retinoblastoma protein-binding domain. However, there appears to be significant clinical and morphological overlap between polyomaviruspositive and polyomavirus-negative Merkel cell carcinoma cases. Although much of the recent focus of Merkel cell carcinoma pathogenesis has been on polyomavirus, the pathogenesis of polyomavirus-negative cases is still poorly understood. We hypothesized that there are underlying human somatic mutations that unify Merkel cell carcinoma pathogenesis across polyomavirus status, and to investigate we performed whole exome sequencing on five polyomavirus-positive cases and three polyomavirus-negative cases. We found that there were no significant differences in the overall number of single-nucleotide variations, copy number variations, insertion/deletions, and chromosomal rearrangements when comparing polyomavirus-positive to polyomavirus-negative cases. However, we did find that the retinoblastoma pathway genes harbored a high number of mutations in Merkel cell carcinoma. Furthermore, the retinoblastoma gene (RB1) was found to have nonsense truncating protein mutations in all three polyomavirus-negative cases; no such mutations were found in the polyomavirus-positive cases. In all eight cases, the retinoblastoma pathway dysregulation was confirmed by immunohistochemistry. Although polyomavirus-positive Merkel cell carcinoma is believed to undergo retinoblastoma dysregulation through viral large T antigen expression, our findings demonstrate that somatic mutations in polyomavirus-negative Merkel cell carcinoma lead to retinoblastoma dysregulation through an alternative pathway. This novel finding suggests that the retinoblastoma pathway dysregulation leads to an overlapping Merkel cell carcinoma phenotype and that oncogenesis occurs through either a polyomavirusdependent (viral large T antigen expression) or polyomavirus-independent (host somatic mutation) mechanism. Modern Pathology (2014) 27, 1073-1087; doi:10.1038/modpathol.2013.235; published online 10 January 2014
Merkel cell carcinoma is a rare neuroendocrine tumor of the skin with an aggressive clinical course and an increased prevalence in the elderly and immunosuppressed. 1 The incidence of Merkel cell carcinoma has increased in the last several decades, and the United States has an estimated incidence rate of 0.32 per 100 000 persons per year. 2 Merkel cell carcinoma has a predilection for sun exposed areas, most often occurring in the head and neck region. 3 There is an overall 5-year survival rate of 40%, with stage being a significant prognosticator. 3, 4 Merkel cell polyomavirus was discovered in Merkel cell carcinoma and found to be clonally integrated in B80% of cases. [5] [6] [7] Merkel cell polyomavirus has a high seroprevalence in the general population and asymptomatic infection begins in childhood. [8] [9] [10] [11] As one of the steps in the proposed mechanism for Merkel cell carcinoma oncogenesis, polyomavirus must integrate into the human genome. 12 Viral integration sites occur throughout the human genome without apparent specificity. 13, 14 Emerging data implicate maintenance and expression of the polyomavirus large T antigen in cell cycle dysregulation and the pathogenesis of viral transformation leading to Merkel cell carcinoma. 12, [15] [16] [17] [18] [19] [20] [21] Although the molecular role of Merkel cell polyomavirus is quickly evolving, the overall biology of Merkel cell carcinoma is poorly understood. Moreover, the presence of polyomavirus alone is not sufficient for carcinogenesis, namely in those Merkel cell carcinoma cases considered as polyomavirusnegative.
With established subpopulations of polyomavirus-positive and polyomavirus-negative Merkel cell carcinoma, there has been interest in defining what similarities and differences exist between these groups, especially with regard to clinical outcomes and histology. To date, there is somewhat controversial data regarding the clinical outcomes between polyomavirus status Merkel cell carcinoma subpopulations. An early Finnish study of 114 Merkel cell carcinoma samples by Sihtu et al 7 showed that polyomavirus-positive cases had a significantly higher (threefold) 5-year overall survival when compared with polyomavirus-negative cases. In a smaller United States study (23 cases) by Bhatia et al, 22 median survival was approximately fourfold longer in polyomavirus-positive cases (86 months) than in polyomavirus-negative cases (20 months). In contrast, three subsequent studies by Handschel et al 23 ( 44 German cases), Schrama et al 24 ( 146 Australian and German cases), and Asioli et al 25 (70 Italian cases) demonstrated that 5-year overall survival is independent of Merkel cell polyomavirus status. Additionally, it does not appear that polyomavirus status influences recurrence-free survival. 24 Although there have been reported subtle, yet statistically significant, nuclear and cytoplasmic differences between polyomaviruspositive and polyomavirus-negative Merkel cell carcinoma as detected by complex morphologic analysis, 26 the two are fairly indistinguishable in routine pathological examination of Merkel cell carcinoma by light microscopy.
Despite the conflicting data regarding the outcome and Merkel cell polyomavirus status, it is clear that there is a phenotypic, morphologic, and clinical overlap between polyomavirus-positive and polyomavirus-negative cases. Although Merkel cell polyomavirus is believed to have a role in the majority of cases, a significant proportion (B20%) of Merkel cell carcinoma is polyomavirus-negative. The existence of Merkel cell polyomavirus-negative cases demonstrates that polyomavirus alone is not sufficient for the development of Merkel cell carcinoma. Thus, it is likely that the Merkel cell carcinoma phenotype develops through distinct, yet convergent, polyomavirus-dependent and polyomavirus-independent mechanisms. The molecular and cellular determinants of these convergent phenotypes have yet to be fully established. In this study, we tested the hypothesis that there are somatically acquired mutations in the human genome, which lead to overlapping morphological and clinical Merkel cell carcinoma phenotypes. We performed whole exome sequencing of polyomavirus-positive and polyomavirus-negative cases as an unbiased approach to detect recurrent somatic mutations in Merkel cell carcinoma and to investigate the possible role of known cancer pathways in Merkel cell carcinoma development.
Materials and methods

Case Selection
The use of human subject material was performed in accordance with guidelines set by the Institutional Review Board of Washington University. Eight total cases from deceased patients were selected for whole exome sequencing from previously published and characterized Merkel cell carcinoma cases for which sufficient tissue from formalin-fixed paraffinembedded blocks was available for DNA testing and confirmatory studies. 13, 27 Clinical characteristics included five patients with metastatic Merkel cell carcinoma and three patients with no reported metastases (summarized in Table 1 ).
Merkel Cell Polyomavirus Detection
Total genomic DNA was extracted from formalinfixed paraffin-embedded tissue blocks as previously described. 13 To determine Merkel cell polyomavirus status, standard polymerase chain reaction was performed using previously published protocols. Briefly, thermocycler conditions were as follows: (1) 55 1 C, 1 min; (2) 95 1 C, 1 min; (3) 95 1 C, 15 sec; (4) 55 1 C, 1 min; and (5) repeat steps 3 and 4 for 35 cycles. Platinum Taq HF (Invitrogen, Grand Island, NY, USA) was used. The MCVPS1 primer set was used to detect Merkel cell polyomavirus as previously published; 5 forward sequence 5 0 -TCAGCGTCCCAG GCTTCAGA-3 0 , reverse sequence 5 0 -TGGTGGTCTCC TCTCTGCTACTG-3 0 . A similarly sized beta-globin product (110 bp) was used as an amplification control (forward sequence 5 0 -ACACAACTGTGTTCA CTAGC-3 0 ; reverse sequence 5 0 -CAACTTCATCCACG TTCACC-3 0 ). Cloned viral plasmid DNA (pMCVR17a) was used as a positive control, and no template reactions and DNA from normal controls were used as negative controls. Polymerase chain reaction products were detected by agarose gel electrophoresis following ethidium bromide staining. Five of the cases had reliably detected Merkel cell polyomavirus by standard polymerase chain reaction (06, 18, 24, 27, and 39) and were considered polyomavirus-positive cases. The other three cases (21, 29 , and 33) were polyomavirusnegative.
To ensure maximal viral sensitivity, we further determined the Merkel cell polyomavirus copy number using a sensitive, previously published real-time polymerase chain reaction assay. 22, 27, 28 Briefly, thermocycler conditions were as follows: (1) 50 1 C, 1 min; (2) 95 1 C, 1 min; (3) 95 1 C, 15 sec; (4) 60 1 C, 1 min; and (5) repeat steps 3 and 4 for 40 cycles. Applied Biosystems (Carlsbad, CA, USA) ABI Taqman assay primers were used for the conserved Merkel cell polyomavirus small T antigen, with the following primer sequences: forward sequence 5 0 -GCAAAAAAACTGTCTGACGTGG-3 0 ; reverse sequence 5 0 -CCACCAGTCAAAACTTTCC CA-3 0 ; probe sequence 5 0 -TATCAGTGCTTTATTC TTTGGTTTGGATTTCCTCCT-3 0 . Cloned MCPyV (pMCV-R17a) viral plasmid was serially diluted and used as the positive control, and no template reactions were used for the negative control. The detection threshold was determined from the threshold cycle (C t ) of the most diluted positive control. The sensitivity of this assay is estimated to be B0.0004 viral copies/cell. 27, 28 Whole Exome Sequencing One microgram of total genomic DNA (as determined by Qubit (Life Technologies, Grand Island, NY, USA)) from each of the eight Merkel cell carcinoma cases was first fragmented to B200-300 base pairs using a Covaris E210 instrument (Covaris Inc., Woburn, MA, USA) then end-repaired and ligated to universal Illumina sequencing adapters. Sequencing libraries were then hybridized to Agilent V4 exome capture probes as per the manufacturer's instructions (Agilent Technologies, Santa Clara, CA, USA). Captured DNA was then subjected to limited cycle polymerase chain reaction amplification (eight cycles) using primers with seven base pair sequence indexes to permit multiplex sequencing. DNA from two to three cases was then pooled in equimolar volumes and each pool was sequenced on a HighSeq2000 lane using 2 Â 101 base pair paired end reads. Base calls and quality scores were generated by the included Casava software (v1.8).
Data Analysis
The resulting FASTQ files were aligned to NBCI build 37.2 of the human reference genome (hg19) using Novoalign (Novocraft, Selangor, Malaysia) with default paired-end parameters. Quality metrics were then calculated using a variety of publicly available software and sequence data were 'cleaned' to mark duplicate reads, recalibrate quality scores, and realigned around known polymorphisms using the Genome Analysis Toolkit (GATK v1.6) 29, 30 (http://www.broadinstitute.org/gatk) and picard tools (http://picard.sourceforge.net). Sequence variation was identified using multiple software tools to capture the full spectrum of DNA variation; singlenucleotide polymorphisms and small (o10 base pairs) insertions and deletions (indels) were determined using samtools 31 (http://samtools.sourceforge.net) to ensure a low false-positive rate; larger indels (410 base pairs) were identified using Pindel 32 (https:// trac.nbic.nl/pindel); translocations were identified using Breakdancer 33 (http://breakdancer.sourceforge. net); and copy number variation was identified using CONTRA 34 (http://contra-cnv.sourceforge.net). Sequence variants were then annotated using the SeattleSeq annotation server (http://gvsbatch.gs. washington.edu/SeattleSeqAnnotation137/index.jsp) and only variants representing coding region changes in at least one transcript, and not present as constitutional polymorphisms in dbSNP (v130) (http://www.ncbi.nlm.nih.gov/projects/SNP), were considered for further analysis. The resulting novel coding region changes were compared with previously published somatic cancer mutations using the COSMIC database (v64) 35, 36 (http://cancer. sanger.ac.uk/cancergenome/projects/cosmic). Further, to ensure that previously described somatic variants were not inadvertently removed from the analysis by filtering known polymorphisms in dbSNP, all detected single-nucleotide variations were compared with COSMIC and manually reviewed. As paired normal tissue was not available for analysis, we could not directly differentiate between coding region changes representing 'personal singlenucleotide polymorphisms' (rare mean allele frequency variants not present in dbSNP) and true somatic mutations. Therefore, we used mutation recurrence among all eight cases to determine which genes were most likely implicated in Merkel cell carcinoma pathogenesis. Coding region variants not present in dbSNP were compared at the gene level (any mutation in the gene) among all cases and segregated by Merkel cell polyomavirus status using custom R scripts (available upon request). High frequency recurrent single-nucleotide variations (present in 4five of eight cases) were further filtered against a laboratory-generated 'blacklist' of falsepositive variants resulting from sequence alignment errors particular to the Agilent V4 exome capture probes. The observed allele fractions of mutations were used to infer co-occurring mutations as has been previously described. 37 
Fluorescence In Situ Hybridization
Interphase fluorescence in situ hybridization for RB1 was performed on formalin-fixed paraffinembedded tissue sections cut at a thickness of 5 mm on positively charged microscope slides. The paraffin was removed from the sections with three washes of 5 min each in CitriSolve. The slides were then hydrated in two washes of absolute ethanol for 1 min each and allowed to air dry. The slides were processed through a pretreatment solution of sodium thiocyanate that had been preheated to 80 1 C. After a 3 min wash in distilled water, the tissue was digested in protease solution (pepsin in 0.2N HCl) for 15 min at 37 1 C, followed by another 3 min wash in distilled water. The slides were allowed to air dry after which they were dehydrated by passing through consecutive 70, 85, and 100 ethanol solutions for 1 min each. The slides were again allowed to air dry before applying prepared probe mixture. Probes used were purchased from Abbott Molecular (Des Plaines, IL, USA) and included Vysis LSI 13 (RB1) 13q14 SpectrumOrange Probe (Catalog no. 05J15-011) and Vysis 13q34 SpectrumGreen fluorescence in situ hybridization Probe Kit-CE (Catalog no. 05N34-020). Probes were diluted at a concentration of 1:50 in tDenHyb-2 hybridization buffer (Insitus Biotechnologies Inc., Albuquerque, NM, USA) and well-mixed. Next, the probe in buffer was applied to the appropriate slide to cover the tissue section and the section was coverslipped. Co-denaturation was achieved by incubating the slides at 73 1 C for 5 min in a slide moat. Hybridization occurred by transferring the slides to a 37 1 C slide light-shielded, humid slide moat overnight. Post hybridization, the coverslips were removed and the slides immersed in 75 1 C wash solution (2XSSC/0.3%NP40) for 2 min followed by a 1 min wash in jar containing the same solution at room temperature. The slides were allowed to air dry in the dark and were then counterstained with 10 ml of DAPI II (Abbott Molecular Inc.). Slides were examined using an Olympus BX60 fluorescent microscope with appropriate filters for SpectrumOrange, SpectrumGreen, and the DAPI counterstain. The signal patterns were documented using a CoolSnap camera and Cyto Vision Imaging System.
Immunohistochemistry
Immunohistochemistry utilized formalin-fixed paraffin-embedded tissue cut at 5 mm sections and floated onto charged slides. Immunohistochemistry for the retinoblastoma protein was performed by Clarient Inc. (Aliso Viejo, CA, USA). Primary antibodies used included retinoblastoma antibody (clone G3-245; BD Biosciences San Jose, CA, USA) at 1:300 dilution for 30 min and phospho-retinoblastoma (Ser807/811) antibody (Catalog 9308; Cell Signaling Technology, Boston, MA, USA) at 1:200 dilution for 1 h. Automated staining was performed using the Bond-III Autostainer (Leica, Buffalo Grove, IL, USA) for retinoblastoma and Ventana Benchmark XT (Ventana Medical, Tucson, AZ, USA) for phospho-retinoblastoma according to the manufacturer's protocol. Pretreatment antigen retrieval strategies included Leica Bond Epitope Retrieval solution 2 (EDTA-based buffer, pH 9.0) for retinoblastoma and a protein citrate buffer (pH 6.0) for phosphoretinoblastoma at 100 1 C. Breast cancer specimens were used as positive staining controls.
Statistics
Comparisons made between groups were performed using the GraphPad Prism software (La Jolla, CA, USA) and the R statistics package (R, version 2.15.1, R Project for Statistical Computing, http://www. r-project.org/). P-values were determined by the use of the two-tailed unpaired t-test. Plots were created in R.
Results
Demographics and Sequence Metrics
Eight cases of Merkel cell carcinoma that have been previously reported were included in this study (representative Merkel cell carcinoma histology shown in Figure 1) . 13, 27 Demographic information is summarized in Table 1 . Five cases were Merkel cell polyomavirus-positive and the other three were polyomavirus-negative as determined by using the MCVPS1 primer set and agarose gel detection. The
Modern Pathology (2014) 27, 1073-1087 average age at diagnosis between the polyomaviruspositive cases (73 years, ± 15 years) and the polyomavirus-negative cases (62 years, ± 10 years) was not significantly different (P ¼ 0.2143). Similarly, the length of time from diagnosis to death between polyomavirus-positive cases (4 years, ± 4 years) and the polyomavirus-negative cases (6 years, ±6 years) was not significantly different (P ¼ 0.4821). All eight cases had a primary site located within the skin and five of eight cases showed metastases to regional lymph nodes. All three of the polyomavirus-negative cases had metastatic disease, whereas only two of the five polyomavirus-positive cases had metastases. Although a small number of cases, this is consistent with some of the controversial literature reporting a more aggressive clinical course related to polyomavirusnegative cases. 7, 22, 38 Whole human exome sequencing was performed on each of the eight Merkel cell carcinoma cases using formalin-fixed paraffin-embedded tissue. The average number of reads generated per case was 130 477 404 (26 GBases). On average, 94.1% of the exome for each case had at least 25 Â coverage. The spectrum of mutations identified include singlenucleotide variations, copy number variations, indels (insertion/deletions), and structural variations. The total number of mutations identified, as well as the type, for each case is summarized in Table 2 . Each case generated an average of 41 768 single-nucleotide variation calls, of which 989 represented novel (not in dbSNP) nonsynonymous variants. There was no significant difference in the total number of variants or novel nonsynonymous variants between polyomavirus-positive and polyomavirus-negative groups (P ¼ 0.5500 and 
Identification of Recurrent Mutation
As paired normal samples were not sequenced along with the Merkel cell carcinoma samples, we could not differentiate between non-pathogenic 'personal single-nucleotide polymorphisms' (low mean allele frequency variants specific to an individual and not present in dbSNP) and true somatically acquired variants. Therefore, we looked for recurrent mutations among the eight Merkel cell carcinoma cases to determine genes critical to pathogenesis. Recurrence was assessed at the gene level (ie, the presence or absence of mutations in TP53). Recurrent mutations are summarized in Table 3 . There were eight highly recurrent nonsynonymous, non-dbSNP gene variants, present in all eight cases. None of these occurred in known cancer-related genes and the same variant for each gene was observed in each case; all were flagged as 'blacklisted' variants representing sequence capture artifact, and these variants were not further analyzed, but are included in the , and 18, respectively. All of these nonsense mutations were predicted to be deleterious by PolyPhen and one (p.W195*) has been previously described in breast cancer (COSMIC ID: COSS1659943). 39 To assess the significance of these findings, we compared the rate of truncating, nonsense RB1 mutations previously reported as somatic variants in all cancer types using the COSMIC database (181 of 12 584 cases) to our data. Assuming a rate of truncating mutation in RB1 of 0.014 for both virus-positive and -negative cases of Merkel cell carcinoma, and considering all possible 2 Â 2 tables with row sums fixed to 5 and 3 (the numbers of polyomavirus-positive and -negative cases), we obtain a highly significant P-value of 5.6 Â 10 À 6 for the finding of nonsense RB1 mutations in all three polyomavirus-negative cases, but none of the five polyomavirus-positive cases.
Identification of RB1 and RB1 Pathway Mutations
On the basis of the finding of truncating RB1 nonsense mutations in three of three polyomavirusnegative Merkel cell carcinoma cases, we sought to determine whether retinoblastoma-related pathway genes were mutated in polyomavirus-positive cases. Further, although the initial recurrence analysis focused only on single base pair variants, we subsequently analyzed a full range of DNA variation including indels, copy number variations, and translocations, to determine whether retinoblastoma pathway mutations were included in a broader class of mutations. Retinoblastoma pathway mutations are summarized in Table 4 . All eight Merkel cell carcinoma cases showed sequence changes predicted to affect at least one of the 14 retinoblastoma pathway genes. The retinoblastoma gene (RB1) itself, was disrupted in five of the eight cases (including the three previously described nonsense mutations, one case with a frame-shift deletion, and one case with RB1 copy loss). The range of RB1 mutations are summarized in Table 5 . Strikingly, all three polyomavirus-negative cases had truncating single-nucleotide variant nonsense mutations, which were located in three separate locations of RB1; all mutations were present with a high variant allele fraction. None of the polyomavirus-positive cases had a nonsense RB1 mutation. Two cases, one polyomavirus-positive and one polyomavirus-negative case, each had a large RB1 deletion, and one polyomavirus-positive case had a small deletion involving RB1. 
Validation of RB1 pathway mutations
Following the discovery phase of mutations in Merkel cell carcinoma, the DNA and protein-level validation of the changes in RB1 observed in whole exome sequencing was performed. First, the RB1 copy number loss detected in two Merkel cell carcinoma cases by whole exome sequencing was confirmed by fluorescence in situ hybridization (Figure 2) . Second, to determine whether mutations detected in the RB1 gene resulted in a corresponding change in retinoblastoma protein expression, we performed immunohistochemistry for the retinoblastoma protein. Retinoblastoma protein showed absent immunoreactivity in each of the five cases with a RB1 mutation discovered by whole exome sequencing ( Figure 3) ; however, the three cases without RB1 mutations by sequencing, showed strong and diffuse nuclear reactivity for the retinoblastoma protein. These results support a one to one relationship with RB1 genetic mutations and corresponding absence of protein.
To further explore the retinoblastoma pathway in Merkel cell carcinoma, immunohistochemistry for phosphorylated-retinoblastoma protein was performed. Under normal regulatory circumstances in actively cycling tumor cells, retinoblastoma protein is phosphorylated, leading to its inactivation as a tumor suppressor, S-phase entry, and cell division. Therefore, in the three Merkel cell Non-polymorphism single-nucleotide variation. Copy number variation. Non-polymorphism single-nucleotide variation and copy number variation.
Indel.
Modern Pathology (2014) 27, 1073-1087 carcinoma cases with detectable retinoblastoma protein expression (Figure 3) , phosphorylation of retinoblastoma protein is expected, given an intact retinoblastoma signaling pathway. However, in all eight cases, there was similar, minimal detectable phosphorylated-retinoblastoma protein, consistent with retinoblastoma dysregulation (Figure 4) .
Comparison of Variant Allele Fractions
To determine whether other gene variants were part of the same founder clone containing RB1 nonsense mutations, arising either before or at the time of the RB1 mutation, we examined the variant allele fraction of single-nucleotide variations as has been previously described. 37 We first examined the allele fraction of single-nucleotide variations present in dbSNP (representing constitutional variants) to non-dbSNP variants (representing 'personal' constitutional variants and true somatically acquired mutations). As expected, although single-nucleotide variations present in dbSNP had allele fractions of 50 or 100% consistent with hetero-or homozygous constitutional Merkel cell and retinoblastoma mutations variants, those not present in the dbSNP showed skewing of the allele fractions indicating the presence of true somatically acquired variants, present at variable allele fractions due to stromal cell dilution, copy number variation, tumor heterogeneity, and so on ( Figure 5 ). RB1 variant allele fractions in the three cases (21, 29 , and 33) with truncating retinoblastoma protein mutations ranged from 76.8 to 92.8%, with a mean of 85.2% ( Figure 6 ). The increased allele fractions of RB1 truncating mutations to greater than 50% likely represent a homozygous mutation within tumor cells, which are diluted in a background of non-tumor cells. However, it is not possible to determine whether the RB1 mutations in each tumor represent a homozygous variant in a heterozygous background vs a homozygous acquired mutation. The number of genes with single-nucleotide variations occurring at an allele frequency ±5% within that of RB1, showed high variability between cases (Supplementary Table 1 ). This set included 10 genes for case 21, 31 genes for case 31, and 210 genes for case 29.
None of the genes with single-nucleotide variations clustering around RB1 were recurrent among all three cases. AGBL5 V695I  ATP13A3 G1024S a ARMC4  D425Y  a ARMC4  D425Y  ADAMTS19 L533F  ACAD10  P55H  ABHD5  R114L  BCL9  S1213L C14orf93 R376H  BSN  P1482L AZI1  P418L  ATP10B  R1023Q ADCY10  E939K  ADAMTS18 P1186S ACSL5  P587L  BTBD19 T76S A29G  EGFR  G719A  FCAR  M61I  CCDC154  V21I  DISC1  S301F  SIGLEC10 R205S  a LYZL2  A29G  OR2M4  T267M  EPX  L72I  a FOXK1  T683P  CDC16  P562L  DNAH5  R2639Q  a SLC25A26 S41N  NF1  D176E  TBC1D16 T189M  FN3KRP  V223I  GABRQ  S286L  DCAF12L2 P334L  FNIP2  G539R  SMCR7L  D398Y  NUP88  I126T  TET2  Y867H  a FOXK1  T683P  LRRC32  E231Q  EPHA3  G633E  FRK  E188K  SPTBN4  V937I  a PLEC  T4429M ZMYND10 R340Q  GCN1L1  L595F  ME1  E227K  FAT3  G618E  GALNT13 R194Q  PRR12  Q772L  a GLUD2  G35R  MLLT6  A327T  FBRSL1  A293T  GBP3  Q136 b  SCGB1C1 E47D  GRM3  E538K  NNMT  E233K  FPR3  R315C  GNA14  E66K  a SLC25A26 S41N  KCNA4  R598W  NTNG1  R336Q  GATA6  E579K  GPR132  R151Q  TCIRG1  R28W  KCNAB1 W231 b  NUCB1  R87 b  GRASP  S387F  GUCY1A2 S712L  TSHZ1  T112P  LMO2  Q126E  OR4K17  A108V  GRIN2A  D1035N HSPG2  G3138R  LPPR5  R246 b  P2RY12  E188K  GRM1  A184T  HYDIN  E1542K  MAP2  S312L  PIK3CA  E545K  HHIP  G64R  LILRA5  R218C  MIER2  D351N  a PLEC  T4429M KCNQ3  E656K  LIMK1  E375K  MYO1G  R641C  PTPRO  E854K  KCNS2  E438K  LRBA  T1588M  NLRP3  R920 b  SIGLEC6  A251T  KIF3A  R206C  a LYZL2  A29G  OR5V1  S313F  SLC24A5  E53K  KIF5A  S831F  MMP7  R127 b  PCSK1N  S4A  a SLC25A26 S41N  MAGEC3  C26Y  MYO18B E2241K  PER1  T866P  SOX5  D221N  MCOLN2  R217W  NOC2L  D699N  PRKD1  D378N  STXBP5L  R789 b  MN1  E1048K a OR11G2 G49D  PTPRS  P287L  a TP53  R196 b  NDN  E257K  OR13C4  D191N  SMARCA1 Q35E  ZCCHC4  D72H  NRXN1  G1406E OR14J1  P280S  TEK  R522C  ZNF717  V230A  NUCB2  R173H  OR6Y1  I118N  TFPI2  R222C  a ZNRF4  S14T  NUP93  E182K  a PCLO  R3831C  TLE6  R165Q  NWD1  E182K  POLB  G80R  TRIM38  P438S  OR10K2  S310F  PRMT7  G206R  ZNF717  V230A  a OR11G2  G49D  RAG2  R148Q  a ZXDB  E122K  PCDHGA1  R293C  RB1  W195 b  a ZXDB  E123A  a PCLO  R1507K SALL2  P719S  PLCXD3  K169E  SAMD11 S171L  POLE  P1601S SCAF1  P22L  PROKR2  R85C  SFMBT1 R195H  PTF1A  R296 b  SLC30A3 A111V  RCOR2  R254Q  TBX18  H401Y  RNF111  S206L  TBX21  R400 b  RRP7A  N65S  TGFBI  M502V  RSPO1  W153 b  a TP53  R156P  RXFP3  S115F  a TP53  R342 b  RYR2  E4137K a TTN  E25755K  SEMA4D V167I 
Discussion
For the first time, whole exome sequencing was used as an unbiased tool to characterize the genetic landscape of Merkel cell carcinoma, utilizing archival formalin-fixed paraffin-embedded tissue. This is in contrast to previous studies that have taken targeted approaches to define somatic mutations in Merkel cell carcinoma. These genes include PIK3-CA, TP53, and PTEN. [40] [41] [42] [43] In our study cases, PIK3CA and TP53, but not PTEN, were found to harbor mutations, but only in small number of cases (Table 5) . Using the gene level recurrence as a metric, we identified the retinoblastoma pathway as critical to Merkel cell carcinoma pathogenesis. We acknowledge, however, that without concurrent exome data from paired normal tissue in each case, we cannot fully exclude that the 'mutations' identified represent benign polymorphisms not present in dbSNP; estimates of such 'personal single-nucleotide variants' are B200 coding region variants per normal individual and are therefore unlikely to account for all variants identified in each case. 44 To further ameliorate this potential source of false discovery, we compared our data with the COSMIC database of known somatic mutations in cancer, looked only for recurrent mutations present in more than one case (and therefore unlikely to represent low prevalence polymorphisms), and examined the variant allele fraction of potential mutations.
Other groups have also provided evidence for retinoblastoma pathway dysregulation in subsets of Merkel cell carcinoma. Merkel cell polyomavirus has a large T antigen LXCXE domain that, when expressed, binds directly to retinoblastoma protein. 45 Several lines of evidence have suggested We found that polyomavirus-negative cases with little or no detectable polyomavirus by sensitive real-time polymerase chain reaction had truncating, nonsense RB1 mutations. Even though two of the five polyomavirus-positive cases showed RB1 deletions (one case with a deletion and one with copy number variation), there were no single-nucleotide variation truncating nonsense mutations within polyomavirus-positive cases. This suggests a unique genetic mechanism to RB1 inactivation occurring within polyomavirus-negative cases; however, given the small sample size in this study, we cannot exclude that such mutations may also be present in polyomavirus-positive cases. Further we note that, Figure 7 Proposed mechanism of Merkel cell carcinoma oncogenesis involving the retinoblastoma pathway. In this model, the retinoblastoma pathway is dysregulated in both Merkel cell polyomavirus (MCPyV)-positive and polyomavirus-negative cases, which leads to an indistinguishable morphological and clinical phenotype.
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Merkel cell and retinoblastoma mutations although two polyomavirus-negative cases had DNA-level mutations in RB1, one resulted in copy loss of RB1, and the other a 68 amino-acid deletion near the C-terminus, and may result in different functional effects than the RB1 truncating mutations seen in polyomavirus-negative cases.
Other groups have reported a similar correlation between retinoblastoma protein expression and Merkel cell polyomavirus copy number. Bhatia et al 22 linked the presence of retinoblastoma protein by immunohistochemistry to cases of Merkel cell carcinoma with a polyomavirus load of at least 0.06 viral copies/cell (n ¼ 9), as detected by real-time polymerase chain reaction. Merkel cell carcinoma cases with polyomavirus viral loads ranging from 0 to 0.0035 viral copies/cell (n ¼ 14) had an absence of retinoblastoma protein. However, a study by Houben et al 49 showed retinoblastoma protein expression by immunohistochemistry in every tested Merkel cell carcinoma case (n ¼ 50), including those with extremely low levels of viral copies/cell. It is possible that the discrepant findings were due to differing antibodies used or antigen retrieval techniques. A recent gene expression study by Harms et al 50 comparing transcripts between Merkel cell polyomavirus-positive and polyomavirusnegative Merkel cell carcinoma cases showed that virus-negative cases have a relative 2.4-fold lower expression of RB1 and that retinoblastoma protein immunohistochemistry corresponded to Merkel cell polyomavirus status and RB1 transcript levels. In this study, we link the presence of decreased retinoblastoma protein expression to specific genetic mutations. Overall, these mutations tend to occur in Merkel cell carcinoma cases with low to no detectable polyomavirus arguing that retinoblastoma abrogation is required for Merkel cell carcinoma pathogenesis in the absence of polyomavirus.
Using an unbiased genomic approach, we identified the retinoblastoma pathway as critical in Merkel cell carcinoma pathogenesis and validated that retinoblastoma protein was decreased or absent in Merkel cell carcinoma cases with RB1 mutations. Further, we demonstrate that in Merkel cell carcinoma cases with intact retinoblastoma protein expression and without the evidence of RB1 mutations, the majority of retinoblastoma protein exists in the active, unphosphorylated form, despite frequent tumor cell division. This finding suggests retinoblastoma protein dysregulation by an alternative pathway in some cases of polyomavirus-positive Merkel cell carcinoma, such as direct large T antigen binding and subsequent non-phosphorylation-dependent inactivation of retinoblastoma protein. On the basis of these findings, we propose a model of Merkel cell carcinoma oncogenesis by which two separate pathways, a polyomavirus-dependent pathway in which retinoblastoma protein is functionally inactivated and a polyomavirus-independent pathway in which RB1 sustains somatic mutation, both of which require retinoblastoma protein dysregulation to produce an overlapping Merkel cell carcinoma phenotype ( Figure 7 ). An alternative explanation for RB1 mutation in Merkel cell carcinoma might include the proposed model of hit-and-run oncogenesis in which Merkel cell polyomavirus integrates in to the host genome of all Merkel cell carcinoma cases, does genetic damage, either persists as clonally integrated virus or is expelled from the human genome by various repair mechanisms. 51 Integrating our data with this model, Merkel cell polyomavirus may initiate Merkel cell carcinoma tumorogenesis in a subset of cases, including a genetic 'hit' to RB1 such as nonsense truncating mutations. After this 'hit' occurs, Merkel cell polyomavirus is no longer necessary for Merkel cell carcinoma progression and maintenance and the virus leaves ('runs' from) the human host genome. In any case, the retinoblastoma pathway appears to have an important role in Merkel cell carcinoma. Therapeutic targeting of the retinoblastoma pathway, specifically downstream of the retinoblastoma protein itself, by small-molecule inhibitors has been proposed in several tumor types with retinoblastoma protein loss (recently reviewed 52 ). Perhaps future research focused on targeting the retinoblastoma pathway in Merkel cell carcinoma may offer clinical benefit for this highly aggressive cancer.
